4.7 Article

Premature Pubarche: Time to Revise the Diagnostic Approach?

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 12, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/jcm12062187

Keywords

non-classic congenital adrenal hyperplasia; early pubarche; 17OH Progesterone; bone age; ACTH test

Ask authors/readers for more resources

Premature pubarche (PP) can be an early manifestation of non-classic congenital adrenal hyperplasia caused by 21 hydroxylase deficiency (NC21OHD). This study evaluated the predictive value of baseline androgens, 17-OHP levels, and auxological features in suggesting the presence of NC21OHD and the need for an ACTH test to confirm the diagnosis. Key predictive features for NC21OHD were identified, including baseline 17 OHP >200 ng/mL, bone age advance >2 years, and DHEA-S levels >228 ng/mL. These findings can help guide diagnostic decisions for patients with PP.
Premature pubarche (PP) could represent the first manifestation of non-classic congenital adrenal hyperplasia caused by 21 hydroxylase deficiency (NC21OHD) (10-30% of cases). In the last 20 years, the necessity of performing an ACTH test to diagnose NC21OHD in all cases with PP has been questioned, with conflicting results. This study aims to retrospectively evaluate the predictive value of the basal androgens, 17-OHP levels, and auxological features in suggesting the presence of NC21OHD and, thus, the need for a standard ACTH test to confirm the diagnosis. In all, 111 consecutive patients (87 females) with PP and advanced bone age underwent an ACTH test. Of these, 6/111 cases (1 male) were diagnosed with NC21OHD. The mean baseline 17 hydroxyprogesterone (17-OHP), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), delta 4 androstenedione (Delta 4A), and testosterone serum levels were higher in NC21OHD patients than in the others (p < 0.05). We found three predictive features for NC21OHD: basal 17 OHP of >200 ng/mL, bone age advance of >2 years, and DHEA-S levels of >228 ng/mL with sensitivity and specificity of 83.3% and 97.1%, 83.3% and 65.7%, and 83.3% and 96.2%, respectively. Our data confirm that the prevalence of NC21OHD is low among patients with PP. Serum 17-OHP of >200 ng/mL could be helpful to decide, in most cases, which patients should undergo the ACTH test. Bone age advance represented an inadequately specific predictive marker of NC21OHD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available